ADMINISTRATION RN LR LU WHAT'S NEW AT CBER What'sNewMainImage Bookmark and Share You are subscribed to  What's New at CBER for the U.S. Food & Drug Administration (FDA) WHAT'S NEW TODAY The following links have been updated recently: Posted: 7/3/2024 * Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2024 - Updated: July 3, 2024 * July 1, 2024 Approval Letter - AFLURIA - DRAFT GUIDANCES - SUBMIT PUBLIC COMMENTS BY JULY 29, 2024 * Considerations for the Use of Human and Animal-Derived Materials in the Manufacture of Cellular and Gene Therapy and Tissue-Engineered Medical Products * Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products * Platform Technology Designation Program for Drug Development - RDEA PILOT PROGRAM CBER and the Center for Drug Evaluation and Research (CDER) began accepting submissions to the Rare Disease Endpoint Advancement (RDEA) Pilot Program in September 2023. This innovative Pilot aims to accelerate rare disease drug development by fostering collaboration between sponsors and the FDA throughout the novel efficacy endpoint development process. The FDA welcomes RDEA submissions on a quarterly basis, with up to one eligible proposal selected per quarter. The deadline for submitting applications this quarter is September 30, 2024. For more information about the Program, visit Rare Disease Endpoint Advancement Pilot Program. Additionally, for guidance on submitting proposals to CBER, visit Submission Deadlines and Process | Rare Disease Endpoint Advancement Pilot Program. If you would like to connect with the FDA RDEA team, please email [email protected]. feedtwitterfacebookInstagramyoutubeflickr Manage Subscriptions  |   |  Help - This email was sent to [email protected] using GovDelivery Communications Cloud on behalf of: U.S. Food and Drug Administration ·  10903 New Hampshire Ave · Silver Spring, MD ·  20993-0002 ·  1-888-INFO-FDA GovDelivery logo